The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary endpoint by reducing cough frequency by 57% when adjusted for placebo results, which was statistically significant, Trevi said.